about
Management of epilepsy in womenManagement of epilepsy during pregnancy: an updatePharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoringPregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewSudden unexpected death in epilepsy. Potential role of antiepileptic drugsFoetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry.Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability.MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION.Pharmacogenetics and individualizing drug treatment during pregnancy.The importance of increased clearance of lamotrigine during pregnancy.Antiepileptic drugs in women with epilepsy during pregnancyLamotrigine dosing for pregnant patients with bipolar disorder.Highlights from the United States Food and Drug Administration's public workshop on the development of animal models of pregnancy to address medical countermeasures in an "at-risk" population of pregnant women: Influenza as a case study.Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies.Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and TechnologyDo the results of pregnancy registries contradict one another?Management of epilepsy during pregnancy.Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment SubcommitInfluence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancyPregnancy, epilepsy, and anticonvulsants.Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in PregnancyCanadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorder in women: reproductive events and treatment considerations.Hormones, seizures, and lamotrigine: Oh, my!Management of epilepsy in women of childbearing age: practical recommendations.Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers.Regulation of hepatic phase II metabolism in pregnant micePharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation.Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders.Currently available antiepileptic drugs.Women and epilepsy: review and practical recommendations.Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies.Trends in maternal deaths from epilepsy in the United Kingdom: a 30-year retrospective review.Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation.Value of therapeutic drug monitoring in epilepsy.Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.
P2860
Q24680158-A64FE40F-F1D2-4386-9C0A-4ABAC7E640EDQ26752470-117DE86D-9B9D-48EF-82DE-626C532C7A5EQ27027293-A7DD60F7-7994-4442-BA85-CEC8E78212EBQ28109657-99D1CFFA-AB1B-4807-B3FA-5D696D0DD5B2Q28278208-912B645A-D5AD-4F13-8A5A-E6BBD4B90C5EQ31046235-7EB87204-3C9C-4FDA-B468-9AEDC216501AQ33610642-37534A5B-4DF4-4C88-9D16-AE3939DE7547Q33683865-74DA5867-CE60-42FE-B69E-0F0DDE1044E1Q33781272-5F173679-4CC0-4428-B347-F063C97F32ACQ33899349-43A97A51-00AB-4A4D-BB99-49B3B7FF5374Q33949402-B78908B4-56A7-4C00-B2FC-4192106DEC19Q34131260-2C2310D6-8E3F-49A8-96A5-181906458E1AQ34442499-BA20956B-BC45-4B6D-A7F8-A72EC85052F6Q34469479-887CB544-D5D1-497D-8C5D-0ABE1B8D7EFAQ34606995-4A9CCBA0-FCEE-4D5D-9764-2ADD126F1D7DQ34623867-9E85F074-D068-483D-B510-C15E863C4067Q34722379-99F496F3-D2B5-44BE-84A6-D5BC49E7715FQ34905287-0A4B2AE2-06E2-4227-BC03-F23817A8C409Q34985706-6508E7AC-B39C-4964-A356-ACAA1B2D006EQ35025745-33ABB86B-2167-476F-9385-9D9AB6126629Q35236942-0AEB110A-96E8-421E-80B6-D9C7C220D024Q35797203-4AD41D39-1436-4091-BC26-7B40DF230A6DQ36161335-9F28B0BC-6049-439E-838A-D3C9D30F66C1Q36181505-F5CEA1A6-2B94-4565-8166-F766C1AF3971Q36453496-3348A3AB-F966-43C3-8139-9CD400841776Q36476623-A9D86C2D-6E95-4D29-BCBE-8233EC33A59CQ36476778-94C5BAB6-C2D9-4E7F-BD3E-132CA0E4FE77Q36497592-EF7F7E71-94DD-43FC-AB18-23197ED20AD3Q36627204-5C806D3C-7A68-4656-814D-421ADD96D3C5Q36660112-2FDF1C4E-EA1C-4E2F-A3E3-A1E9590866CEQ36662879-9AA3BB22-E6A0-468B-9330-295F4F5C754CQ36662898-0A70D807-61D3-4D74-88B2-A820DE19BF26Q36673011-0183A9D8-5BAD-4E3E-8A03-651C1FBA42BAQ36697463-06140D4B-1D76-43C4-A68C-4F521C66E98AQ36752925-D0F95F1A-AE9B-4108-85C6-1CA72A09CB20Q36862763-5B459B68-6097-4BC9-B76E-F0399E7E58F7Q37070406-2BF1909F-F9FA-4A08-883F-877632362CAAQ37148955-E4A43E27-10DA-44B4-A055-59E9BB8477BAQ37174056-FBDE5BBD-B988-4402-9469-78FF8F0F61CAQ37179423-7FDDC2AD-5B86-4278-BFE6-E08B62CBF533
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Lamotrigine clearance during pregnancy.
@en
Lamotrigine clearance during pregnancy.
@nl
type
label
Lamotrigine clearance during pregnancy.
@en
Lamotrigine clearance during pregnancy.
@nl
prefLabel
Lamotrigine clearance during pregnancy.
@en
Lamotrigine clearance during pregnancy.
@nl
P2093
P356
P1433
P1476
Lamotrigine clearance during pregnancy.
@en
P2093
P304
P356
10.1212/WNL.59.2.251
P407
P577
2002-07-01T00:00:00Z